CRISPR Therapeutics AG
Insider trading & Transactions

Last updated:

Transaction Date Insider Security Shares Price per share Total value Source
Sale
DYLAN-HYDE TYLER officer: Chief Legal Officer
 Common Shares 7,240 $18.04 $130,588
Sale
NOVAK RODGER director, officer: President
 Common Shares 47,706 $18.09 $862,906
Purchase
BOLZON BRADLEY J PHD director
 Common Stock 161,000 $14 $2,254,000
Purchase
LUNDBERG SVEN ANTE officer: Chief Scientific Officer
 Common Shares 400 $14 $5,600
Purchase
WOIWODE THOMAS director
 Common Stock 161,000 $14 $2,254,000
Purchase
CELGENE CORP /DE/ 10 percent owner
 Common Stock 800,150 $14 $11,202,100
Purchase
GEORGE SIMEON director
 Common Shares 66,500 $14 $931,000
Purchase
GLAXOSMITHKLINE PLC 10 percent owner
 Common Shares 66,500 $14 $931,000
Purchase
VERSANT VENTURE CAPITAL IV, L.P. 10 percent owner
 Common Stock 161,000 $14 $2,254,000
Purchase
EMSTER KURT VON director
 Common Shares 56,000 $14 $784,000

Showing 550 to 560 of 560 results.

Insider trading

Monitoring trades made by the management members or major shareholders of companies may help create a sharper picture of what is happening inside the companies. Base your decisions on buys or sells of the people involved and do the right thing at the right time.

Who is insider?

Every director or senior officer, as well as any other entity or individual owning more than 10% of the company’s shares on the stock market, is called an insider. Such people or entities are allowed to buy/sell the company's shares under strictly controlled conditions. Key premise here is that none of them can make trades based on non-public information about the company.

Similar companies insider trading: